Who
John R. Moore
General Counsel
Company insider
Files Form 4 as: General Counsel, Edgewise Therapeutics; VP, General Counsel, Array Biopharma; Director, Nivalis Therapeutics.
In numbers
- Trades disclosed
- 201
- Buys
- 0
- Sells
- 44
- Bought
- $0
- Sold
- $6.0M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 17 Feb 2006
- Last trade
- 12 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 17 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Aug 2026filed 17 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —6,718 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $107K2,439 at $43.81 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,718 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,500 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,62059 at $44.41 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,40699 at $44.50 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $106K2,419 at $43.80 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,718 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,500 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —6,718 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $107K2,439 at $43.81 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,62059 at $44.41 | filing |
News
No headline names them, or the companies they trade most, lately.